NCT04837716 2026-02-19
Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
4 trialsNCT07354061 2026-01-21
TD-ENSEMBLE
Tang-Du Hospital
Phase 1/2 Not yet recruiting
NCT07235306 2025-11-19
Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT02767804 2025-10-14
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Xcovery Holdings, Inc.
Phase 3 Active not recruiting